Health Technology Assessment Specialist (HTA)

Core responsibility: an HTA Specialist systematically evaluates the clinical effectiveness, cost-effectiveness, and health system impact of a drug, device, or medical technology to inform reimbursement, adoption, or public health policy decisions.

In practice, this means conducting systematic literature reviews to synthesize existing clinical evidence, building cost-effectiveness and budget impact models comparing a new technology against current standard practice, and preparing HTA reports or policy briefs that health authorities use to decide whether a technology should be adopted, and at what price. An HTA Specialist working on a new diagnostic test for a government health scheme, for example, might spend months building a model comparing the test's cost against its likely impact on earlier diagnosis and treatment outcomes, then present findings to a technical appraisal committee deciding whether the test should be funded nationally.

What an HTA Specialist is not: this is not the same as a Regulatory Affairs Specialist, whose job is getting a product legally approved to enter the market at all, since HTA work happens after or alongside regulatory approval and focuses specifically on value and adoption decisions, not safety and efficacy approval. HTA work is also fundamentally evidence synthesis and policy-facing, not primary clinical research generation.

Preferred backgrounds: an M.Sc. or Ph.D. in Health Economics, Public Health, Pharmacoeconomics, or a related quantitative health field, since HTA work demands genuine depth in both economic modeling and evidence synthesis methodology.

Acceptable backgrounds: M.Pharm graduates with a health economics or research focus, and MPH graduates, are commonly hired at entry to mid levels, particularly in industry-side HTA and market access roles.

Rare but possible: candidates from a purely clinical or biostatistics background occasionally transition into HTA work, typically after building specific health economics and cost-effectiveness modeling skills separately.

Experience requirements: hands-on exposure to systematic literature review and basic economic modeling, even at a dissertation or academic research level, is what most entry-level government and industry roles actually screen for. Government HTA positions like those at HTAIn often specify formal minimum experience thresholds, sometimes two years or more, with a Ph.D. or relevant advanced degree sometimes counted toward that requirement.

Fresher pathway: possible but narrower than operational clinical roles, particularly for government-affiliated HTA research positions, though industry-side HEOR and HTA-adjacent roles at consulting firms are more genuinely open to fresh postgraduates with strong quantitative training.

What separates HTA Specialists who move into senior policy or program leadership roles from those who stay at the analyst level is the ability to connect a technical economic model to a real, defensible policy recommendation that a government body or payer will actually act on, not just produce a technically correct analysis in isolation.

The short version: HTA work and HEOR work overlap heavily and are often performed by the same people, but HTA specifically centers on the formal, structured process of deciding whether a health system should adopt or pay for a technology, while HEOR is the broader discipline of building economic and clinical value evidence that feeds into that HTA decision, among other uses.

Entry-level HTA and pharmacoeconomics research roles in India typically start between ₹5 and 8 LPA, based on current government and industry postings, with government-affiliated research positions, such as those at AIIMS or ICMR-linked HTA projects, sometimes offering closer to ₹5 to 6 LPA (around ₹50,000 per month) for research assistant-level roles requiring HTA and cost-effectiveness analysis skills. With experience, professionals in industry-side HTA and HEOR roles move into the ₹9 to 18 LPA range, and senior HTA leads or HEOR Directors overseeing HTA strategy at multinational pharma companies can earn ₹25 LPA and above, particularly those with experience navigating both Indian and international HTA frameworks like NICE, CADTH, or PBAC.

The typical ladder runs: HTA Analyst or Research Associate, then HTA Specialist, then Senior Researcher or Manager, then HTA Program Lead or Director of Value and Evidence.

If you are coming from a health economics, public health, or pharmacy background and want to know whether HTA is a realistic fit for your specific interests, whether in government policy or industry market access, book a 1:1 session with us.

HEOR Analyst / Market Access

Real World Evidence Scientist

Biostatistician

Healthcare Actuary

AI-assisted literature review and evidence synthesis tools are increasingly used to accelerate the most time-consuming part of HTA work, screening and extracting data from published studies, which traditionally took weeks of manual review for a single technology assessment.

This is also reshaping the pace at which HTA bodies and pharma companies can respond to new evidence, with AI-assisted modeling increasingly used to run multiple economic scenarios faster than manual modeling allowed, though the final judgment on which scenario is most realistic still requires a trained analyst.

What remains fundamentally human is the policy judgment behind translating a technical cost-effectiveness finding into a real, defensible recommendation that a government body or payer will actually adopt, since that requires weighing economic evidence against genuinely human considerations like equity, public trust, and health system capacity that no model can fully capture. For anyone entering this field, the practical takeaway is that HTA specialists who combine AI-assisted evidence synthesis speed with strong policy judgment and genuine understanding of the Indian health system are best positioned as the country's HTA infrastructure continues to expand.